Immunotherapy in GRIN2A-negative Landau-Kleffner Syndrome

Minerva Pediatr. 2020 Apr;72(2):139-141. doi: 10.23736/S0026-4946.19.05419-7.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Agnosia / drug therapy
  • Anticonvulsants / therapeutic use
  • Aphasia / drug therapy
  • Child
  • Female
  • Humans
  • Hydrocortisone / administration & dosage
  • Hydrocortisone / therapeutic use*
  • Immunoglobulins / therapeutic use*
  • Landau-Kleffner Syndrome / drug therapy
  • Landau-Kleffner Syndrome / therapy*
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / therapeutic use*
  • Receptors, N-Methyl-D-Aspartate*
  • Treatment Outcome

Substances

  • Anticonvulsants
  • Immunoglobulins
  • Receptors, N-Methyl-D-Aspartate
  • N-methyl D-aspartate receptor subtype 2A
  • Hydrocortisone
  • Methylprednisolone